A phase 2A trial recently received confirmation to proceed in investigating psilocybin-assisted psychotherapy in the treatment of adult patients with IBS.
KELOWNA, BC / ACCESSWIRE / July 13, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused
Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
InvestorNewsBreaks – Tryp Therapeutics Inc (CSE: TRYP) (OTCQB: TRYPF) to Proceed with Phase 2A Clinical Trial in Patients with IBS streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.